RN1001(Avotermin) in Scar Improvement Following Breast Augmentation
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This will be a multi-centre, double-blind, within-subject, placebo controlled randomised
trial in female subjects. All subjects will undergo bilateral breast augmentation surgery.
Immediately following surgery, each subject will receive 100µl containing 50ng or 200ng of
RN1001 per linear centimetre intradermally into both margins of one breast wound, and 100µl
of placebo solution per linear centimetre intradermally into both margins of their other
breast wound. The allocation of treatment to wound (left or right) will be randomised and
double blind.